Morgan Stanley Has $220,000 Stock Position in Zafgen Inc (NASDAQ:ZFGN)

Share on StockTwits

Morgan Stanley raised its holdings in Zafgen Inc (NASDAQ:ZFGN) by 150.8% in the 2nd quarter, HoldingsChannel reports. The fund owned 184,606 shares of the biopharmaceutical company’s stock after acquiring an additional 110,989 shares during the period. Morgan Stanley’s holdings in Zafgen were worth $220,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. AWM Investment Company Inc. increased its position in Zafgen by 32.4% in the 2nd quarter. AWM Investment Company Inc. now owns 1,857,171 shares of the biopharmaceutical company’s stock valued at $2,210,000 after acquiring an additional 454,874 shares during the period. Northeast Financial Consultants Inc acquired a new position in Zafgen in the 2nd quarter valued at approximately $28,000. Jacobs Levy Equity Management Inc. increased its position in Zafgen by 165.3% in the 2nd quarter. Jacobs Levy Equity Management Inc. now owns 177,540 shares of the biopharmaceutical company’s stock valued at $211,000 after acquiring an additional 110,610 shares during the period. A.R.T. Advisors LLC acquired a new position in Zafgen in the 2nd quarter valued at approximately $35,000. Finally, Gabelli Funds LLC acquired a new position in Zafgen in the 2nd quarter valued at approximately $26,000. Hedge funds and other institutional investors own 79.88% of the company’s stock.

ZFGN opened at $0.75 on Friday. Zafgen Inc has a twelve month low of $0.63 and a twelve month high of $10.08. The company has a quick ratio of 5.11, a current ratio of 5.11 and a debt-to-equity ratio of 0.28. The company has a fifty day moving average of $0.73 and a 200-day moving average of $1.24. The stock has a market cap of $28.14 million, a PE ratio of -0.39 and a beta of -0.57.

Zafgen (NASDAQ:ZFGN) last posted its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.27) by $0.03. Sell-side analysts anticipate that Zafgen Inc will post -1.15 EPS for the current fiscal year.

Several equities analysts have issued reports on the stock. Wedbush cut shares of Zafgen from an “outperform” rating to a “neutral” rating and decreased their price target for the company from $6.00 to $0.78 in a research report on Friday, September 6th. Roth Capital cut shares of Zafgen from a “buy” rating to a “neutral” rating in a research report on Friday, September 6th. ValuEngine upgraded shares of Zafgen from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Zacks Investment Research reiterated a “hold” rating on shares of Zafgen in a research report on Saturday, October 19th. Finally, JMP Securities cut shares of Zafgen from an “outperform” rating to a “market perform” rating in a research report on Thursday, September 5th. Eight equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $6.05.

Zafgen Company Profile

Zafgen, Inc, a clinical-stage biopharmaceutical company, develops therapies for patients suffering from metabolic diseases comprising type 2 diabetes, Prader-Willi syndrome (PWS), and other metabolically related disorders. The company's lead product candidate is ZGN-1061, a fumagillin-class methionine aminopeptidase 2 (MetAP2) inhibitor administered by subcutaneous injection, which is in Phase 2 clinical trial and profiled for its utility in the treatment of type 2 diabetes and other related metabolic disorders.

Featured Story: Ex-Dividend

Want to see what other hedge funds are holding ZFGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zafgen Inc (NASDAQ:ZFGN).

Institutional Ownership by Quarter for Zafgen (NASDAQ:ZFGN)

Receive News & Ratings for Zafgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zafgen and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Metropolitan Life Insurance Co NY Acquires 9,443 Shares of ZIOPHARM Oncology Inc.
Metropolitan Life Insurance Co NY Acquires 9,443 Shares of ZIOPHARM Oncology Inc.
Metropolitan Life Insurance Co NY Cuts Stock Position in Paylocity Holding Corp
Metropolitan Life Insurance Co NY Cuts Stock Position in Paylocity Holding Corp
Metropolitan Life Insurance Co NY Sells 14,000 Shares of Washington Prime Group Inc
Metropolitan Life Insurance Co NY Sells 14,000 Shares of Washington Prime Group Inc
Metropolitan Life Insurance Co NY Has $239,000 Stock Holdings in Trupanion Inc
Metropolitan Life Insurance Co NY Has $239,000 Stock Holdings in Trupanion Inc
Metropolitan Life Insurance Co NY Raises Holdings in Focus Financial Partners Inc
Metropolitan Life Insurance Co NY Raises Holdings in Focus Financial Partners Inc
NanoString Technologies Inc  Shares Purchased by Metropolitan Life Insurance Co NY
NanoString Technologies Inc Shares Purchased by Metropolitan Life Insurance Co NY


© 2006-2019 Ticker Report